Palo Alto Investors LP - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 132 filers reported holding REVANCE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.62 and the average weighting 0.5%.

Quarter-by-quarter ownership
Palo Alto Investors LP ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$59,972,145
-54.7%
5,228,6090.0%5.67%
-46.9%
Q2 2023$132,336,094
-22.0%
5,228,609
-0.8%
10.69%
-24.0%
Q1 2023$169,753,432
+74.0%
5,270,209
-0.3%
14.06%
+69.1%
Q4 2022$97,535,422
-18.0%
5,283,609
+19.9%
8.32%
-11.6%
Q3 2022$118,936,000
+95.4%
4,405,0390.0%9.40%
+77.2%
Q2 2022$60,878,000
-29.3%
4,405,039
-0.2%
5.31%
-20.3%
Q1 2022$86,106,000
+20.8%
4,415,689
+1.1%
6.66%
+46.1%
Q4 2021$71,308,000
-20.1%
4,369,366
+36.5%
4.56%
-15.4%
Q3 2021$89,204,000
-6.0%
3,201,8660.0%5.38%
+2.9%
Q2 2021$94,903,000
+6.0%
3,201,8660.0%5.23%
+2.6%
Q1 2021$89,492,000
+18.1%
3,201,866
+19.8%
5.10%
+28.4%
Q4 2020$75,762,000
+51.1%
2,673,313
+34.0%
3.97%
+44.3%
Q3 2020$50,152,000
+20.5%
1,994,905
+17.0%
2.75%
+10.2%
Q2 2020$41,621,000
+356.8%
1,704,372
+176.8%
2.50%
+227.5%
Q1 2020$9,112,000
+533.7%
615,705
+595.0%
0.76%
+865.8%
Q4 2019$1,438,000
-7.5%
88,590
+10.2%
0.08%
-31.9%
Q3 2014$1,554,000
-50.1%
80,369
-12.3%
0.12%
-50.0%
Q2 2014$3,117,000
-46.0%
91,669
-50.0%
0.23%
-2.9%
Q1 2014$5,776,000183,3380.24%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q1 2020
NameSharesValueWeighting ↓
Essex Woodlands Management, Inc. 3,342,047$94,714,00024.58%
Palo Alto Investors LP 2,673,313$75,762,0003.97%
Evolutionary Tree Capital Management, LLC 89,348$2,532,0001.93%
RICE HALL JAMES & ASSOCIATES, LLC 1,121,152$31,773,0001.12%
ArrowMark Colorado Holdings LLC 2,964,135$84,004,0000.65%
Rhenman & Partners Asset Management AB 220,000$6,235,0000.51%
Fosun International Ltd 233,841$6,627,0000.43%
OSTERWEIS CAPITAL MANAGEMENT INC 174,970$4,959,0000.30%
ESSEX INVESTMENT MANAGEMENT CO LLC 76,671$2,173,0000.27%
Tekla Capital Management LLC 213,808$6,059,0000.21%
View complete list of REVANCE THERAPEUTICS INC shareholders